(Q38680250)

5 September 2017

Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

5 September 2017

1 reference

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26707137%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

4

Hashem B El-Serag

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26707137%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

3

Jennifer R Kramer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26707137%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

5

Fasiha Kanwal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26707137%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Michael Lin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26707137%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

26 December 2015

1 reference

Digestive Diseases and Sciences

5 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26707137%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26707137%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26707137%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

1714-1720

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26707137%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10620-015-4000-6

10 June 2020

exact match

0 references

cites work

Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

Dyslipidemia in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

Statin use in patients with cirrhosis: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

Statins and hepatotoxicity: focus on patients with fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-4000-6

Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

12 December 2020

An assessment of statin safety by hepatologists

1 reference

12 December 2020

Nonalcoholic fatty liver disease is underrecognized in the primary care setting.

1 reference

12 December 2020

Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study

1 reference

12 December 2020

An assessment by the Statin Liver Safety Task Force: 2014 update

1 reference

12 December 2020